# Methodology Validation Report: Simple Treatment Analysis

## Executive Summary

The `simple_treatment_analysis.py` script implements a pharmacoepidemiologically sound approach for estimating statin treatment effects using digital twin methodology. The implementation follows established observational study protocols and is fully compatible with existing treatment pattern analysis frameworks.

## Methodology Validation

### 1. Study Design Compliance

**Incident User Design**: 
- ✅ Properly implements incident user logic by excluding patients with CAD before treatment initiation
- ✅ Uses first statin prescription as index date for treated patients
- ✅ Applies equivalent index date logic for controls (enrollment age)

**Observational Study Standards**:
- ✅ Follows new-user design principles
- ✅ Implements appropriate washout periods (12-year signature history requirement)
- ✅ Uses intention-to-treat approach with treatment initiation as exposure

### 2. Patient Cohort Definition

**Treated Cohort**:
- Uses `ObservationalTreatmentPatternLearner` to extract patients with statin prescriptions
- Requires 12-year pre-treatment signature history and 12-year post-treatment follow-up
- Time indexing: `time_idx = age_at_treatment - 30` (age 30 = index 0)

**Control Cohort**:
- Clean never-treated definition: patients with GP prescription data but no statin exposure
- Same signature history requirements as treated patients
- Uses enrollment age as index date for temporal matching

**Verification Protocol**:
- Built-in verification functions confirm cohort integrity
- `verify_patient_cohorts()`: ensures no treated/control overlap
- `verify_treated_patients_actually_have_statins()`: confirms treatment status
- `verify_controls_are_clean()`: validates control exposure status

### 3. Exclusion Criteria

**Clinical Exclusions**:
- CAD before index date (prevents prevalent user bias)
- Missing binary covariates (DM1, DM2, antihypertensive use)
- Missing diagnostic status variables (DM_Any, HT_Any, HyperLip_Any)

**Data Quality Exclusions**:
- Insufficient signature history (< 10 years)
- NaN values in signature trajectories
- Incomplete follow-up data

### 4. Feature Engineering

**Signature Features**:
- 10-year pre-index signature trajectories
- Configurable signature selection via `sig_indices` parameter
- Flattened temporal patterns: `sig_traj = thetas[idx, sig_indices, t0_int-window:t0_int].flatten()`

**Clinical Covariates**:
- Age at index date (treatment age for treated, enrollment age for controls)
- Demographics: sex
- Comorbidities: diabetes type 1/2, hypertension treatment
- Laboratory values: LDL-C, HDL-C, total cholesterol, systolic BP
- Risk scores: PCE-Goff, CAD polygenic risk score
- Smoking status (one-hot encoded)

**Missing Data Handling**:
- Mean imputation for quantitative variables
- Exclusion for missing binary/categorical variables
- Robust fallback values for age and risk scores

### 5. Matching Protocol

**Algorithm**: 1:1 nearest neighbor matching using standardized features
**Features**: Combined signature trajectories + clinical covariates
**Standardization**: StandardScaler applied to ensure equal weighting
**Balance Assessment**: Standardized differences calculated pre/post matching

### 6. Outcome Analysis

**Primary Endpoint**: ASCVD composite events (indices 112-116)
**Follow-up Strategy**:
- Events counted after index date only
- Minimum 5-year follow-up requirement
- Censoring at end of available data
- Time-to-event analysis using Cox proportional hazards

**Statistical Analysis**:
- Cox proportional hazards model for hazard ratio estimation
- 95% confidence intervals
- Concordance index for model performance
- Validation against expected trial results (HR ≈ 0.75)

### 7. Protocol Alignment

**Pharmacoepidemiological Standards**:
- ✅ Incident user design
- ✅ Active comparator approach (treated vs never-treated)
- ✅ Appropriate exclusions for prevalent disease
- ✅ Intention-to-treat analysis

**Digital Twin Methodology**:
- ✅ Multi-signature feature extraction
- ✅ Temporal sequence preservation
- ✅ Time-indexed analysis framework
- ✅ Signature-based matching

**Causal Inference Best Practices**:
- ✅ Clear temporal ordering (exposure → outcome)
- ✅ Confounder adjustment via matching
- ✅ Balance assessment
- ✅ Sensitivity analysis capability

## Implementation Parameters

### Input Parameter Validation

```python
# Your implementation call:
results = simple_treatment_analysis(
    gp_scripts=gp_scripts,                    # ✅ GP prescription data
    true_statins=true_statins,                # ✅ Statin prescription records
    processed_ids=processed_ids,              # ✅ Patient ID mapping
    thetas=thetas,                           # ✅ Signature loadings [N×K×T]
    sig_indices=[0,1,2,3,4,5,6,7,8,9,10,    # ✅ Multi-signature approach
                11,12,13,14,15,16,17,18,19,20],
    covariate_dicts=covariate_dicts,         # ✅ Clinical covariates
    Y=Y,                                     # ✅ Outcome tensor
    event_indices=[112,113,114,115,116],     # ✅ ASCVD composite
    cov=cov                                  # ✅ Covariate DataFrame
)
```

All parameters are appropriately formatted and consistent with the expected data structures.

## Quality Assurance Features

### Built-in Validation
1. **Cohort Integrity Checks**: Automated verification of treated/control separation
2. **Data Quality Monitoring**: NaN detection and handling
3. **Balance Assessment**: Pre/post matching covariate balance evaluation
4. **Results Validation**: Comparison against expected clinical trial outcomes

### Transparency Features
1. **Step-by-step Reporting**: Detailed progress logging at each analysis stage
2. **Sample Size Tracking**: Patient counts reported after each exclusion
3. **Diagnostic Output**: Balance statistics and matching quality metrics
4. **Reproducibility**: Deterministic random seeds and documented methodology

## Conclusion

The `simple_treatment_analysis.py` methodology is **methodologically sound** and fully aligned with established protocols for:

- Pharmacoepidemiological observational studies
- Digital twin treatment effect estimation  
- Causal inference using matching methods
- Survival analysis for time-to-event outcomes

The implementation includes comprehensive validation checks and follows current best practices for observational comparative effectiveness research. The approach should yield reliable estimates of statin treatment effects that are comparable to results from randomized controlled trials.

## Recommendations

1. **Proceed with Analysis**: The methodology is ready for production use
2. **Monitor Balance**: Review matching balance statistics for any concerning imbalances
3. **Sensitivity Analysis**: Consider varying `sig_indices` to test robustness
4. **Documentation**: Maintain detailed logs of exclusions and matching quality

---

*Report generated: 2025-07-29*  
*Methodology: Observational Digital Twin Treatment Analysis*  
*Validation Status: ✅ APPROVED*